Weiheng Chen

Weiheng Chen

Partner

An Accomplished Transactional Practitioner

Weiheng has represented clients in some of the largest and most significant M&A and capital market deals involving Chinese companies.
Capital Markets Veteran

Weiheng has represented issuers and underwriters in scores of securities offerings, including Hong Kong IPOs and HKSE listings, and NYSE and NASDAQ listings.
Comprehensive Transactions Experience

In addition to M&A and capital markets deals, Weiheng has substantial experience with private equity and venture capital investment, going-private, joint venture, and restructuring transactions.
Broad Industry Experience

Weiheng has represented clients in several business sectors, including the technology, media, telecom, healthcare, education, consumer, and financial industries.

Weiheng Chen is a senior partner at Wilson Sonsini Goodrich & Rosati, where he heads the firm's Greater China practice.

Weiheng's practice is focused on cross-border mergers and acquisitions, private equity, and capital markets transactions in Asia. He has represented clients in connection with some of the largest and most significant M&A and capital market deals in a variety of industries, including technology, media and telecom, healthcare, education, consumer, and financial institutions. He also has worked on a large number of private equity and venture capital investment, going-private, joint venture, and restructuring transactions involving private equity and venture capital firms and multinational corporations. In addition, Weiheng has advised on many high-profile securities offerings, including Hong Kong IPOs and HKSE listings, and SEC-registered offerings and NYSE and NASDAQ listings. He has extensive experience representing both issuers and underwriters.

Weiheng started his legal career in New York, and has been residing in Hong Kong since 2003. He splits his time among the firm's offices in Asia, located in Hong Kong, Beijing, and Shanghai.

Experience

Weiheng Chen is a senior partner at Wilson Sonsini Goodrich & Rosati, where he heads the firm's Greater China practice.

Weiheng started his legal career in New York, and has been residing in Hong Kong since 2003. He splits his time among the firm's offices in Asia, located in Hong Kong, Beijing, and Shanghai.

Education

LL.M., Harvard Law School
Master of Jurisprudence and LL.B., Peking University Law School

Honors

Designated as one of the "World's Leading Private Equity Lawyers" by IFLR/Euromoney
Named to "The A-List: China's Elite Lawyers (Visionary category)" by China Business Law Journal
Recognized as a "notable practitioner" by IFLR 1000

Admissions

State Bar of New York
Hong Kong

Credentials

Education

LL.M., Harvard Law School
Master of Jurisprudence and LL.B., Peking University Law School

Honors

Designated as one of the "World's Leading Private Equity Lawyers" by IFLR/Euromoney
Named to "The A-List: China's Elite Lawyers (Visionary category)" by China Business Law Journal
Recognized as a "notable practitioner" by IFLR 1000

Admissions

State Bar of New York
Hong Kong

Select Representations

Represented Boyu Capital, CDH Investments, Centurium Capital, Sequoia Capital, Silver Lake, Warburg Pincus, and other private equity and growth capital funds in connection with various investment and M&A transactions
Represented technology and healthcare companies such as Tencent, DJI International, and WuXi Pharma in their various investment and financing matters
Advised on the Hong Kong IPOs and HKSE listings of WuXi XDC, LEPU ScienTech Medical Technology, Angel Align Technology, Ascentage Pharma, WuXi AppTec, Wanka Online, WuXi Biologics, Rici Healthcare, Universal Medical, PW MedTech, Dongpeng Holdings, Alibaba.com, Bank of China, and China Shenhua Energy
Advised on the U.S. public offerings and/or listings of Agora, Ebang International, Tencent Music Entertainment, X Financial, Opera Limited, Puxin Education, Bright Scholar, China Biologic Products, Autohome, China Nepstar Chain Drugstore, and Mindray Medical
Provided underwriter-side representation to investment banks, including Goldman Sachs, Deutsche Bank, Morgan Stanley, CICC, Citi, JP Morgan, Credit Suisse, Bank of America, and UBS
Represented Lumentum in the $750 million acquisition of Cloud Light Technology Group
Represented Boyu Capital in the acquisition of Quasar Medical
Represented PW Medtech and the acquisition consortium in the $4.6 billion going-private transaction of China Biologic Products, Inc.
Represented Warburg Pincus and the acquisition consortium in the $9.7 billion going-private transaction of 58.com
Represented SilverLake-led investors in the $2.3 billion PIPE investments in TAL Education
Represented the acquisition consortium led by Yunfeng Capital and Alibaba and Boyu Capital in the $1.5 billion going-private transaction of iKang Healthcare
Represented the acquisition consortium in the HK$5.6 billion going-private transaction of Dongpeng Holdings
Represented the management shareholders and the acquisition consortium in the $3.3 billion going-private transaction of WuXi PharmaTech
Represented OmniVision Technologies in its $1.9 billion acquisition by a Chinese consortium of investors
Represented Integrated Silicon Solution Inc. in its $640 million sale to a Chinese consortium of investors
Represented the acquisition consortium in the $1.9 billion going-private transaction of Shanda Games
Represented the founder and the acquisition consortium in the $3 billion going-private transaction of Giant Interactive
Represent RDA Microelectronics in its $900 million merger with Tsinghua Unigroup
Represented TJOY Holdings in the $400 million sale of its China skincare business to Coty, Inc.
Represented State Grid International Development in its $1.72 billion acquisition of power transmission assets in Brazil
Represented Waste Management Inc. in its waste-to-energy joint venture with Shanghai Chentou Holdings in China
Represented China Huaneng Group in its $3 billion acquisition of Tuas Power in Singapore
Represented C-BONS International in the €270 million sale of its China haircare business to Beiersdorf AG
Represented CVC Partners in its sale of Adisseo France SAs to ChemChina
Represented Bank of China in connection with its strategic sales to Royal Bank of Scotland, UBS, Temasek, and Asian Development Bank
Represented Thomson in the combination of its global television business with TCL

Matters

Select Representations

Represented Boyu Capital, CDH Investments, Centurium Capital, Sequoia Capital, Silver Lake, Warburg Pincus, and other private equity and growth capital funds in connection with various investment and M&A transactions
Represented technology and healthcare companies such as Tencent, DJI International, and WuXi Pharma in their various investment and financing matters
Advised on the Hong Kong IPOs and HKSE listings of WuXi XDC, LEPU ScienTech Medical Technology, Angel Align Technology, Ascentage Pharma, WuXi AppTec, Wanka Online, WuXi Biologics, Rici Healthcare, Universal Medical, PW MedTech, Dongpeng Holdings, Alibaba.com, Bank of China, and China Shenhua Energy
Advised on the U.S. public offerings and/or listings of Agora, Ebang International, Tencent Music Entertainment, X Financial, Opera Limited, Puxin Education, Bright Scholar, China Biologic Products, Autohome, China Nepstar Chain Drugstore, and Mindray Medical
Provided underwriter-side representation to investment banks, including Goldman Sachs, Deutsche Bank, Morgan Stanley, CICC, Citi, JP Morgan, Credit Suisse, Bank of America, and UBS
Represented Lumentum in the $750 million acquisition of Cloud Light Technology Group
Represented Boyu Capital in the acquisition of Quasar Medical
Represented PW Medtech and the acquisition consortium in the $4.6 billion going-private transaction of China Biologic Products, Inc.
Represented Warburg Pincus and the acquisition consortium in the $9.7 billion going-private transaction of 58.com
Represented SilverLake-led investors in the $2.3 billion PIPE investments in TAL Education
Represented the acquisition consortium led by Yunfeng Capital and Alibaba and Boyu Capital in the $1.5 billion going-private transaction of iKang Healthcare
Represented the acquisition consortium in the HK$5.6 billion going-private transaction of Dongpeng Holdings
Represented the management shareholders and the acquisition consortium in the $3.3 billion going-private transaction of WuXi PharmaTech
Represented OmniVision Technologies in its $1.9 billion acquisition by a Chinese consortium of investors
Represented Integrated Silicon Solution Inc. in its $640 million sale to a Chinese consortium of investors
Represented the acquisition consortium in the $1.9 billion going-private transaction of Shanda Games
Represented the founder and the acquisition consortium in the $3 billion going-private transaction of Giant Interactive
Represent RDA Microelectronics in its $900 million merger with Tsinghua Unigroup
Represented TJOY Holdings in the $400 million sale of its China skincare business to Coty, Inc.
Represented State Grid International Development in its $1.72 billion acquisition of power transmission assets in Brazil
Represented Waste Management Inc. in its waste-to-energy joint venture with Shanghai Chentou Holdings in China
Represented China Huaneng Group in its $3 billion acquisition of Tuas Power in Singapore
Represented C-BONS International in the €270 million sale of its China haircare business to Beiersdorf AG
Represented CVC Partners in its sale of Adisseo France SAs to ChemChina
Represented Bank of China in connection with its strategic sales to Royal Bank of Scotland, UBS, Temasek, and Asian Development Bank
Represented Thomson in the combination of its global television business with TCL

Recent Insights

Client Highlights

On October 21, 2024, all the conditions precedent under the subscription agreement dated October 7, 2024, entered into between WuXi AppTec Co., Ltd. (WuXi AppTec), WuXi AppTec (HongKong) Limited (WuXi HK), and Citigroup Global Markets Limited have been fulfilled and the issue of the US$500,000,000 zero coupon guaranteed convertible bonds due 2025 (the Bonds) in an aggregate principal amount of US$500,000,000 was completed. The net proceeds from the subscription of the Bonds, after the deduction of fees, commissions and expenses, will be approximately US$494.4 million, and will be utilized in the following manner: (a) approximately 70 percent will be used for global expansion; (b) approximately 20 percent will be used for refinancing indebtedness; and (c) approximately 10 percent will be used for general corporate purposes. The listing of and permission to deal in the Bonds on The Stock Exchange of Hong Kong Limited will become effective from October 22, 2024.

Learn More

Client Highlights

On October 7, 2024 (after trading hours), WuXi AppTec (HongKong) Limited (WuXi HK), WuXi AppTec Co., Ltd (WuXi AppTec), and Citigroup Global Markets Limited entered into a subscription agreement in connection with the proposed issuance and subscription of US$500 million zero coupon guaranteed convertible bonds due 2025. Such bonds are convertible at the option of the holder thereof into the Hong Kong-listed H Shares of WuXi AppTec (Proposed Bond Issue) at a conversion price of HK$80.02 per share. WuXi AppTec will unconditionally and irrevocably guarantee the due payment of all sums expressed to be payable by WuXi HK under the Proposed Bond Issue.

Learn More

View All

Recent Events

WSGR Events

Please join Wilson Sonsini for MCLE Virtual Series – Session 1. We will be providing a half-day of professional educational sessions on a wide range of topics, including most of the MCLE categories in California, New York, Texas and Washington, among other states.

Learn More